Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358409 · ClinicalTrials.gov registry record · Early Phase 1
Regression of Myocardial Steatosis by Nebivolol
A Early Phase 1 study of Cardiac Steatosis and Lipotoxicity, sponsored by Lidia Szczepaniak.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01358409 is a Early Phase 1 study of Cardiac Steatosis and Lipotoxicity that has completed, run by Lidia Szczepaniak. The registered enrollment target is 31 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01358409, a Early Phase 1 study of Cardiac Steatosis and Lipotoxicity, has completed, sponsored by Lidia Szczepaniak.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
Within large number of patients with obesity, it is crucial to determine who is at the greatest risk for development of chronic heart disease. The investigators previous studies suggest that an excessive accumulation of fat in heart cells precedes the development of obesity-related pathologies and may serve as a biomarker of heart disease in high-risk population. Until now, the evaluation of fat in the human heart was possible postmortem or by biopsy. The investigators novel magnetic resonance spectroscopy technique enables the quantification of intracellular lipid content non-invasively and repeatedly in humans in vivo. It could be used to better screen and treat obese patients at risk for the development of metabolic disease. The investigators hypothesize that in obese humans with elevated myocardial triglycerides, treatment with Nebivolol will reduce myocardial fat and will improve heart function.
Conditions Studied
Interventions
- DRUG Nebivolol
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-04-01 |
| Est. Completion | 2013-02-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358409
The ClinicalTrials.gov registry entry for NCT01358409 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lidia Szczepaniak, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cardiac Steatosis and Lipotoxicity appearing as the primary indexed condition, and to 1 intervention - of which Nebivolol is the first listed.
NCT01358409 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01358409 about?
NCT01358409 is a clinical study titled "Regression of Myocardial Steatosis by Nebivolol". Within large number of patients with obesity, it is crucial to determine who is at the greatest risk for development of chronic heart disease. The investigators previous studies suggest that an excessive accumulation of fat in heart cells precedes the development of obesity-related pathologies and m...
What is the current status of trial NCT01358409?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 31 participants. The study started on 2011-04-01. Estimated completion is 2013-02-11.
What conditions does trial NCT01358409 study?
This clinical trial studies the following conditions: Cardiac Steatosis and Lipotoxicity.
What interventions are being tested in trial NCT01358409?
The interventions under investigation include: Nebivolol (DRUG).
Who is sponsoring clinical trial NCT01358409?
This trial is sponsored by Lidia Szczepaniak, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01358409 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.